Back to resultsA Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. (PASCA)
Primary Purpose
Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
PASCA intervention
Sponsored by
About this trial
This is an interventional prevention trial for Late Effects focused on measuring Late Effects, Survivors, Adults, Screening, Tertiary prevention, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years old and ≤ 65 years old.
- Follow-up at the Léon Bérard center
Treated by chemotherapy for one of the following pathologies, and confirmed by the reference diagnostic technique :
- acute myeloid leukemia;
- Hodgkin's lymphoma;
- aggressive non-Hodgkin's lymphoma;
- primary non-metastatic invasive breast carcinoma;
- testicular germ cell tumor treated with at least 3 courses of BEP (bleomycin, etoposide, cisplatin), 4 courses of EP (etoposide, cisplatin) or 4 courses of VIP (etoposide, ifosfamide, cisplatin) received;
- high-grade soft tissue sarcoma, osteosarcoma or Ewing's sarcoma.
- As a complete response at the end of treatment consultation. If end-of-treatment evaluation is not available at the time of inclusion: as an assumed complete response in the opinion of the investigator based on the previous assessment of response.
- Whose capacity to practice an adapted physical activity will have been certified by a medical certificate issued by the investigating physician, the general practitioner or the referring physician.
- Able to understand, read and write French.
- Available and willing to participate in the project throughout the duration of the study.
- Living in the Auvergne-Rhône-Alpes region or in the department of Saône-et-Loire
- Affiliated with a health insurance plan.
- Having declared an attending physician.
- Having signed and dated the informed consent.
Exclusion Criteria:
- With a history of malignancy other than basal cell skin cancer.
- Cannot be followed for medical, social, family, geographical or psychological reasons for the duration of the study.
- Participating in other studies that could impact on the evaluation of the judgement criteria.
- Deprived of liberty by judicial or administrative decision.
Sites / Locations
- Centre Leon BerardRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PASCA intervention
Arm Description
Outcomes
Primary Outcome Measures
Incidence of social precariousness
Diagnosed by a social worker
Change from Baseline return to work issues incidence at 60 months
Diagnosed by a social worker
Change from Baseline cognitive problems incidence at 60 months
Diagnosed by a neurologist
Change from Baseline anxiety crises incidence at 60 months
Diagnosed by a psychologist or psychiatrist
Change from Baseline depressive events incidence at 60 months
Questionnaire "HADS-D" (Hospital Anxiety and Depression scale)
Change from Baseline chronic fatigue incidence at 60 months
Questionnaire "MFI-20" (Multidimensional Fatigue Inventory)
Change from Baseline physical deconditioning incidence at 60 months
A value below the lower limit on at least two of the following physical tests
Six-Minute Walk Test (6MWT) (meters)
Hand Grip Strength Test (Kg)
Five Times Sit to Stand Test (number)
Flamingo Test (sec)
Change from Baseline overweight/obesity incidence at 60 months
BMI
Waist circumference
Change from Baseline chronic pain incidence at 60 months
Duration of pain
Questionnaire "DN4" (Douleur Neuropathique en 4 questions)
Change from Baseline dermatological disorders incidence at 60 months
Common Terminology Criteria for Adverse Events (CTCAE) v5
Change from Baseline gastrointestinal disorders incidence at 60 months
Common Terminology Criteria for Adverse Events (CTCAE) v5
Change from Baseline sexual disorders incidence at 60 months
Questionnaire "Sexualité VICAN5"
Change from Baseline hypogonadism incidence at 60 months
Presence of clinical signs as defined by the International Society for Sexual Medicine
A value below the lower limit on at least one of the following blood assay:
level of total testosterone
level of bioavailable testosterone
Change from 24 months premature ovarian failure incidence at 60 months
level of Follicle stimulating hormone
level of estradiol
Change from Baseline osteoporosis incidence at 60 months
T-score evaluated by osteodensitometry, on the lumbar spine and upper end of the femur
Change from Baseline chronic kidney failure incidence at 60 months
Diagnosed on the basis of 2 blood tests within 3 months using the same technique showing a decrease in GFR to < 60ml/min/1.73m2, estimated from creatinine levels using the CKD-EPI equation (Chronic Kidney Disease EPIdemiology collaboration, Levey, 2009), albuminuria or proteinuria positive, hematuria, leukocyturia > 10/mm3, or morphological abnormality on renal ultrasound.
Change from Baseline heart failure incidence at 60 months
Diagnosed by a cardiologist with an echocardiography performing the Left Ventricular Ejection Fraction (LVEF) estimate
Change from Baseline coronary heart disease incidence at 60 months
Diagnosed by a cardiologist conducting at least an interrogation with clinical examination, an estimation of pre-test probability of coronary artery disease
Change from Baseline respiratory failure incidence at 60 months
Forced Vital Capacity
Forced expiratory volume in 1 second
Vital capacity
Tiffeneau ratio
Peak expiratory flow
Total lung capacity
Diffusing Capacity Of The Lungs For Carbon Monoxide
Change from Baseline hypothyroidism incidence at 60 months
level of thyroid-stimulating hormone
level of total thyroxine
Change from Baseline lymphedema incidence at 60 months
Diagnosed by a vascular physician with a perimetric measurement of arms and forearms
Change from Baseline second primary cancers incidence at 60 months
Pathology report recorded in the patient file.
Secondary Outcome Measures
Evaluate the PASCA program: referrals made through the network
Number of referrals made through the network (attending physicians, specialist physicians, supportive care services or other health professionals)
Evaluate the PASCA program: time between patient referral and completion of the first consultation
Average time (days) between patient referral and completion of the first consultation
Evaluate the PASCA program: patient characteristics
Comorbidities at diagnosis
Tumor classification
cytogenetics mutations
types and doses of each cancer treatments
ratio of the number of patients included / number of eligible patients
Evaluation of the impact of program adherence on the evolution of the number of complications detected over time
Measurement of the association between program adherence rate and the number of complications detected over time
Evaluation of the impact of program adherence on quality of life.
Measurement of the association between program adherence rate and the overall score on the secondary dimensions of quality of life.
Description of the PASCA network : characteristics of health professionals sensitive to the post-treatment issues.
number of health professionals affiliated with the network
type of health professionals affiliated with the network
distribution over the Auvergne-Rhône-Alpes region according to medical speciality and department
Identification of risk factors associated with complications occurring during follow-up.
Measurement of the association between suspected risk factors and the occurrence of a type of complication, during the duration of follow-up.
Description of the Global Longitudinal Strain
Evolution of the Global Longitudinal Strain in absolute value, relative to a later value
Description of the Left Ventricular Ejection Fraction
Evolution of the Left Ventricular Ejection Fraction relative to a later value
Description of the troponin I level
Evolution of the troponin I level relative to a later value
Description of the Glomerular Filtration Rate
Evolution of the Glomerular Filtration Rate estimated by the CKD-EPI equation relative to a later value
Description of spirometry values
Evolution of spirometry values relative to later values :
Forced Vital Capacity
Forced expiratory volume in 1 second
Vital capacity
Tiffeneau ratio
Peak expiratory flow
Incidence of diabetes mellitus
Level of fasting blood glucose
Incidence of untreated high blood pressure
Measure of systolic blood pressure
Incidence of hypertriglyceridemia
Level of triglyceridemia
Incidence of hyper-LDL-cholesterolemia
Level of LDL-cholesterolemia
Incidence of low level of physical activity
Questionnaire "Godin-Shephard Leisure-Time Physical Activity"
Incidence of insufficiency / deficiency of 25(OH) vitamin D (D2+D3)
Level of 25(OH) vitamin D (D2+D3)
Description of carcinogenic products consumption (tobacco, alcohol, cannabis)
Number of packages years
Questionnaire "DETA-Cage"
Evaluation of the Progression-free survival
Evaluation of the Progression-free survival
Evaluation of the Survival without an increase in the number of complications, among those studied
Evaluation of the Survival without an increase in the number of complications, among those studied
Evaluation of the event-free survival
Evaluation of the event-free survival
Full Information
NCT ID
NCT04671693
First Posted
December 3, 2020
Last Updated
August 29, 2023
Sponsor
Centre Leon Berard
Collaborators
Malakoff-Humanis, Fondation Apicil, Fédération Leucémie Espoir, Biogaran, Le défi Anthony, Novartis, Roche Pharma AG
1. Study Identification
Unique Protocol Identification Number
NCT04671693
Brief Title
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
Acronym
PASCA
Official Title
Study of Complications Related to Treatments in Adults Aged 18 to 65 Years Old Responding to a First Treatment in Oncology or Onco-hematology and Participating in the PASCA (PArcours de Santé au Cours du CAncer) Post-treatment Program.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 24, 2020 (Actual)
Primary Completion Date
January 24, 2028 (Anticipated)
Study Completion Date
April 24, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Leon Berard
Collaborators
Malakoff-Humanis, Fondation Apicil, Fédération Leucémie Espoir, Biogaran, Le défi Anthony, Novartis, Roche Pharma AG
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
INTRODUCTION: Approximately 44% of cancer survivors experience a deteriorated quality of life 5 years after diagnosis due to late onset of complications related to cancer treatments. The objective of the study is to evaluate the incidence rates of treatment-related complications, identify sub-clinical abnormalities and risk factors in patients participating in the PASCA post-treatment program.
METHOD: PASCA is a single-center, interventional cohort study of adult patients who received at least chemotherapy and with a complete remission to a testicular germ cell tumor, primary non-metastatic invasive breast carcinoma, high-grade soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, acute myeloid leukemia, Hodgkin's or aggressive non-Hodgkin's lymphoma. Four assessment visits will be scheduled at 1 month (T1), 6 months (T2), 24 months (T3) and 60 months (T4) after completion of treatment. During these visits, 22 complications will be screened and follow-up care will be systematically offered to the health professional concerned by the complication in case of a positive result. The screening will contain the following elements: screening self-questionnaires, quality of life questionnaire, 12 biological parameters, a urinalysis evaluating hematuria, proteinuria, and leukocyturia, a spirometry, an electrocardiogram, 5 tests evaluating physical condition, vital signs and the perimetric measurement between both arms.
DISCUSSION: This systematic screening could highlight a number of complications occurring after cancer treatments. Sub-clinical abnormalities and new risk factors could also be identified. This new organization of care could improve the quality of life of adult cancer survivors.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Late Effects, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Adult, Stage IIC, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma
Keywords
Late Effects, Survivors, Adults, Screening, Tertiary prevention, Testicular Germ Cell Tumor Mixed, Non-Metastatic Breast Carcinoma, Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, Acute Myeloid Leukemia, Hodgkin Disease, Non Hodgkin Lymphoma
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
All patients in the study will benefit from the PASCA post-treatment program with 4 visits : at 1 month (T1), 6 month (T2), 24 month (T3) and 60 month (T4) after the end of treatment.
Masking
None (Open Label)
Allocation
N/A
Enrollment
858 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
PASCA intervention
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
PASCA intervention
Intervention Description
At each study visit (T1 = 1 month, T2 = 6 months, T3 = 24 months, T4 = 60 months), an exhaustive screening of complications as well as associated sub-clinical abnormalities and risk factors previously identified as such in the literature, will be conducted.
Management of complications consists of referring the patient to a healthcare professional belonging to the PASCA network based on the test results. Referral is defined by referring to pre-established decision trees. It is made to a specialist physician, a health professional from the paramedical field or the patient's general practitioner who confirms the diagnosis if necessary and initiates the patient's care and follow-up. These patients also receive their usual follow-up in the context of their tumor pathology in oncology and onco-hematology.
Primary Outcome Measure Information:
Title
Incidence of social precariousness
Description
Diagnosed by a social worker
Time Frame
Month 1
Title
Change from Baseline return to work issues incidence at 60 months
Description
Diagnosed by a social worker
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline cognitive problems incidence at 60 months
Description
Diagnosed by a neurologist
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline anxiety crises incidence at 60 months
Description
Diagnosed by a psychologist or psychiatrist
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline depressive events incidence at 60 months
Description
Questionnaire "HADS-D" (Hospital Anxiety and Depression scale)
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline chronic fatigue incidence at 60 months
Description
Questionnaire "MFI-20" (Multidimensional Fatigue Inventory)
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline physical deconditioning incidence at 60 months
Description
A value below the lower limit on at least two of the following physical tests
Six-Minute Walk Test (6MWT) (meters)
Hand Grip Strength Test (Kg)
Five Times Sit to Stand Test (number)
Flamingo Test (sec)
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline overweight/obesity incidence at 60 months
Description
BMI
Waist circumference
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline chronic pain incidence at 60 months
Description
Duration of pain
Questionnaire "DN4" (Douleur Neuropathique en 4 questions)
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline dermatological disorders incidence at 60 months
Description
Common Terminology Criteria for Adverse Events (CTCAE) v5
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline gastrointestinal disorders incidence at 60 months
Description
Common Terminology Criteria for Adverse Events (CTCAE) v5
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline sexual disorders incidence at 60 months
Description
Questionnaire "Sexualité VICAN5"
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline hypogonadism incidence at 60 months
Description
Presence of clinical signs as defined by the International Society for Sexual Medicine
A value below the lower limit on at least one of the following blood assay:
level of total testosterone
level of bioavailable testosterone
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from 24 months premature ovarian failure incidence at 60 months
Description
level of Follicle stimulating hormone
level of estradiol
Time Frame
Month 24, Month 60
Title
Change from Baseline osteoporosis incidence at 60 months
Description
T-score evaluated by osteodensitometry, on the lumbar spine and upper end of the femur
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline chronic kidney failure incidence at 60 months
Description
Diagnosed on the basis of 2 blood tests within 3 months using the same technique showing a decrease in GFR to < 60ml/min/1.73m2, estimated from creatinine levels using the CKD-EPI equation (Chronic Kidney Disease EPIdemiology collaboration, Levey, 2009), albuminuria or proteinuria positive, hematuria, leukocyturia > 10/mm3, or morphological abnormality on renal ultrasound.
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline heart failure incidence at 60 months
Description
Diagnosed by a cardiologist with an echocardiography performing the Left Ventricular Ejection Fraction (LVEF) estimate
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline coronary heart disease incidence at 60 months
Description
Diagnosed by a cardiologist conducting at least an interrogation with clinical examination, an estimation of pre-test probability of coronary artery disease
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline respiratory failure incidence at 60 months
Description
Forced Vital Capacity
Forced expiratory volume in 1 second
Vital capacity
Tiffeneau ratio
Peak expiratory flow
Total lung capacity
Diffusing Capacity Of The Lungs For Carbon Monoxide
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline hypothyroidism incidence at 60 months
Description
level of thyroid-stimulating hormone
level of total thyroxine
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline lymphedema incidence at 60 months
Description
Diagnosed by a vascular physician with a perimetric measurement of arms and forearms
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Change from Baseline second primary cancers incidence at 60 months
Description
Pathology report recorded in the patient file.
Time Frame
Month 1, Month 6, Month 24, Month 60
Secondary Outcome Measure Information:
Title
Evaluate the PASCA program: referrals made through the network
Description
Number of referrals made through the network (attending physicians, specialist physicians, supportive care services or other health professionals)
Time Frame
Month 6, Month 24, Month 60
Title
Evaluate the PASCA program: time between patient referral and completion of the first consultation
Description
Average time (days) between patient referral and completion of the first consultation
Time Frame
Month 6, Month 24, Month 60
Title
Evaluate the PASCA program: patient characteristics
Description
Comorbidities at diagnosis
Tumor classification
cytogenetics mutations
types and doses of each cancer treatments
ratio of the number of patients included / number of eligible patients
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Evaluation of the impact of program adherence on the evolution of the number of complications detected over time
Description
Measurement of the association between program adherence rate and the number of complications detected over time
Time Frame
Month 6, Month 24, Month 60
Title
Evaluation of the impact of program adherence on quality of life.
Description
Measurement of the association between program adherence rate and the overall score on the secondary dimensions of quality of life.
Time Frame
Month 6, Month 24, Month 60
Title
Description of the PASCA network : characteristics of health professionals sensitive to the post-treatment issues.
Description
number of health professionals affiliated with the network
type of health professionals affiliated with the network
distribution over the Auvergne-Rhône-Alpes region according to medical speciality and department
Time Frame
Month 6, Month 24, Month 60
Title
Identification of risk factors associated with complications occurring during follow-up.
Description
Measurement of the association between suspected risk factors and the occurrence of a type of complication, during the duration of follow-up.
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Description of the Global Longitudinal Strain
Description
Evolution of the Global Longitudinal Strain in absolute value, relative to a later value
Time Frame
Month 6, Month 24, Month 60
Title
Description of the Left Ventricular Ejection Fraction
Description
Evolution of the Left Ventricular Ejection Fraction relative to a later value
Time Frame
Month 6, Month 24, Month 60
Title
Description of the troponin I level
Description
Evolution of the troponin I level relative to a later value
Time Frame
Month 6, Month 24, Month 60
Title
Description of the Glomerular Filtration Rate
Description
Evolution of the Glomerular Filtration Rate estimated by the CKD-EPI equation relative to a later value
Time Frame
Month 6, Month 24, Month 60
Title
Description of spirometry values
Description
Evolution of spirometry values relative to later values :
Forced Vital Capacity
Forced expiratory volume in 1 second
Vital capacity
Tiffeneau ratio
Peak expiratory flow
Time Frame
Month 6, Month 24, Month 60
Title
Incidence of diabetes mellitus
Description
Level of fasting blood glucose
Time Frame
Month 6, Month 24, Month 60
Title
Incidence of untreated high blood pressure
Description
Measure of systolic blood pressure
Time Frame
Month 6, Month 24, Month 60
Title
Incidence of hypertriglyceridemia
Description
Level of triglyceridemia
Time Frame
Month 6, Month 24, Month 60
Title
Incidence of hyper-LDL-cholesterolemia
Description
Level of LDL-cholesterolemia
Time Frame
Month 6, Month 24, Month 60
Title
Incidence of low level of physical activity
Description
Questionnaire "Godin-Shephard Leisure-Time Physical Activity"
Time Frame
Month 6, Month 24, Month 60
Title
Incidence of insufficiency / deficiency of 25(OH) vitamin D (D2+D3)
Description
Level of 25(OH) vitamin D (D2+D3)
Time Frame
Month 6, Month 24, Month 60
Title
Description of carcinogenic products consumption (tobacco, alcohol, cannabis)
Description
Number of packages years
Questionnaire "DETA-Cage"
Time Frame
Month 1, Month 6, Month 24, Month 60
Title
Evaluation of the Progression-free survival
Description
Evaluation of the Progression-free survival
Time Frame
Month 6, Month 24, Month 60
Title
Evaluation of the Survival without an increase in the number of complications, among those studied
Description
Evaluation of the Survival without an increase in the number of complications, among those studied
Time Frame
Month 6, Month 24, Month 60
Title
Evaluation of the event-free survival
Description
Evaluation of the event-free survival
Time Frame
Month 6, Month 24, Month 60
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years old and ≤ 65 years old.
Follow-up at the Léon Bérard center
Treated by chemotherapy for one of the following pathologies, and confirmed by the reference diagnostic technique :
acute myeloid leukemia;
Hodgkin's lymphoma;
aggressive non-Hodgkin's lymphoma;
primary non-metastatic invasive breast carcinoma;
testicular germ cell tumor treated with at least 3 courses of BEP (bleomycin, etoposide, cisplatin), 4 courses of EP (etoposide, cisplatin) or 4 courses of VIP (etoposide, ifosfamide, cisplatin) received;
high-grade soft tissue sarcoma, osteosarcoma or Ewing's sarcoma.
As a complete response at the end of treatment consultation. If end-of-treatment evaluation is not available at the time of inclusion: as an assumed complete response in the opinion of the investigator based on the previous assessment of response.
Whose capacity to practice an adapted physical activity will have been certified by a medical certificate issued by the investigating physician, the general practitioner or the referring physician.
Able to understand, read and write French.
Available and willing to participate in the project throughout the duration of the study.
Living in the Auvergne-Rhône-Alpes region or in the department of Saône-et-Loire
Affiliated with a health insurance plan.
Having declared an attending physician.
Having signed and dated the informed consent.
Exclusion Criteria:
With a history of malignancy other than basal cell skin cancer.
Cannot be followed for medical, social, family, geographical or psychological reasons for the duration of the study.
Participating in other studies that could impact on the evaluation of the judgement criteria.
Deprived of liberty by judicial or administrative decision.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Romain BUONO, PharmD, MPH
Phone
+33469856358
Email
romain.buono@lyon.unicancer.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Meyssane DJEBALI, Msc
Phone
+33469856358
Email
meyssane.djebali@lyon.unicancer.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mauricette MICHALLET, PhD, MD
Organizational Affiliation
Centre Leon Berard
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Leon Berard
City
Lyon
ZIP/Postal Code
69373
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mauricette MICHALLET, MD
Phone
+33469856358
Email
mauricette.michallet@lyon.unicancer.fr
First Name & Middle Initial & Last Name & Degree
Jean-Yves BLAY, MD
First Name & Middle Initial & Last Name & Degree
Thomas BACHELOT
First Name & Middle Initial & Last Name & Degree
Helen BOYLE
First Name & Middle Initial & Last Name & Degree
Aude FLECHON
First Name & Middle Initial & Last Name & Degree
Christelle DE LA FOUCHARDIERE
First Name & Middle Initial & Last Name & Degree
Pierre-Etienne HEUDEL
First Name & Middle Initial & Last Name & Degree
Pierre SAINTIGNY
First Name & Middle Initial & Last Name & Degree
Olivier TREDAN
First Name & Middle Initial & Last Name & Degree
Philippe TOUSSAINT
First Name & Middle Initial & Last Name & Degree
Mehdi BRAHMI
First Name & Middle Initial & Last Name & Degree
Alice BONNEVILLE-LEVARD
First Name & Middle Initial & Last Name & Degree
Armelle DUFRESNE
First Name & Middle Initial & Last Name & Degree
Anne-Sophie MICHALLET
First Name & Middle Initial & Last Name & Degree
Clemence SANTANA
First Name & Middle Initial & Last Name & Degree
Béatrice FERVERS
First Name & Middle Initial & Last Name & Degree
Marie Adele DAMMACCO
First Name & Middle Initial & Last Name & Degree
Christelle FAURE
First Name & Middle Initial & Last Name & Degree
Jean-François BRANTUS
First Name & Middle Initial & Last Name & Degree
Mellie HEINEMANN
First Name & Middle Initial & Last Name & Degree
Léa ROSSI
First Name & Middle Initial & Last Name & Degree
Violette MESDAG
First Name & Middle Initial & Last Name & Degree
Raphaelle PICARD
First Name & Middle Initial & Last Name & Degree
Nicolas CHOPIN
First Name & Middle Initial & Last Name & Degree
Mélodie CARBONNAUX
First Name & Middle Initial & Last Name & Degree
Philippe REY
First Name & Middle Initial & Last Name & Degree
Yann GUILLERMIN
First Name & Middle Initial & Last Name & Degree
Laure LEBRAS
First Name & Middle Initial & Last Name & Degree
Emmanuelle NICOLAS-VIRELIZIER
First Name & Middle Initial & Last Name & Degree
Amine BELHABRI
First Name & Middle Initial & Last Name & Degree
Souad ASSAAD
First Name & Middle Initial & Last Name & Degree
Franck-Emmanuel NICOLINI
First Name & Middle Initial & Last Name & Degree
Benoite MERY
First Name & Middle Initial & Last Name & Degree
Jessica SERRAND
First Name & Middle Initial & Last Name & Degree
Séverine RACADOT
First Name & Middle Initial & Last Name & Degree
Waisse WAISSI
First Name & Middle Initial & Last Name & Degree
Aude VISY
First Name & Middle Initial & Last Name & Degree
Paul POU
First Name & Middle Initial & Last Name & Degree
Clémence BONDU
First Name & Middle Initial & Last Name & Degree
Ronan TANGUY
First Name & Middle Initial & Last Name & Degree
Cécile LAUDE
First Name & Middle Initial & Last Name & Degree
Coralie MONCHARMONT
First Name & Middle Initial & Last Name & Degree
Christian CARRIE
First Name & Middle Initial & Last Name & Degree
Pierre MEEUS
First Name & Middle Initial & Last Name & Degree
François GOUIN
First Name & Middle Initial & Last Name & Degree
Armelle VINCENEUX
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
We'll reach out to this number within 24 hrs